Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 4/20 | 0.44 |
| ▸ | CA2 | P00918 | 4/20 | 0.44 |
| ▸ | ACHE | P22303 | 2/20 | 0.44 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA4 | P22748 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.44 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.44 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.43 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9814047 | 0.86 | KDM4E (0.53) | KDM4ECA1CA2ACHEHDAC4 | |
| SCHEMBL13712993 | 0.86 | KDM4E (0.47) | KDM4ELPAR1CA1CA2ACHE | |
| SCHEMBL30363481 | 0.84 | GABRA1 (0.44) | KDM4ELPAR1CA1CA2HDAC4 | |
| SCHEMBL11063118 | 0.84 | GABRA1 (0.44) | KDM4ELPAR1CA1CA2HDAC4 | |
| SCHEMBL27510370 | 0.84 | GABRA1 (0.44) | KDM4ELPAR1CA1CA2HDAC4 | |
| Bromide SCHEMBL28922144 | 0.84 | KDM4E (0.51) | KDM4ECA1CA2ACHEHDAC4 | |
| SCHEMBL13651181 | 0.83 | CYP1A2 (0.41) | KDM4ELPAR1CA1CA2ACHE | |
| SCHEMBL13778072 | 0.83 | TSHR (0.44) | KDM4ELPAR1CA1CA2ACHE | |
| Methyl Alcohol SCHEMBL27577395 | 0.82 | KDM4E (0.54) | KDM4ELPAR1CA1CA2ACHE | |
| Chloromethane SCHEMBL27930402 | 0.82 | KDM4E (0.50) | KDM4ECA1CA2ACHEHDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228469-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2024-07-11 | — | — | US | disclosed |
| US-20240217951-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2024-07-04 | — | — | US | disclosed |
| US-20240217951-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2024-07-04 | — | — | US | disclosed |
| US-20240018139-A1 | NEW SMALL-MOLECULE COMPOUNDS FOR CONTROLLING ENDOSOMAL TOLL-LIKE RECEPTORS AND THERAPEUTIC AGENT FOR AUTOIMMUNE DISEASES USING SAME | S＆K THERAPEUTICS (KR) | 2024-01-18 | — | — | US | disclosed |
| US-20200288710-A1 | SUBSTITUTED SULPHONAMIDES FOR CONTROLLING ANIMAL PESTS | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2020-09-17 | — | — | US | disclosed |
| EP-3429355-B1 | SUBSTITUTED SULFONYLAMIDE FOR COMBATING ANIMAL PESTS | BAYER CROPSCIENCE AG (DE) | 2020-02-05 | — | — | EP | disclosed |
| US-20170355703-A1 | COMPOUNDS FOR THE INHIBITION OF INDOLEAMINE-2,3-DIOXYGENASE | MERCK PATENT GMBH (DE) | 2017-12-14 | — | — | US | disclosed |
| US-9771370-B2 | Compounds for the inhibition of indoleamine-2,3-dioxygenase | MERCK PATENT GMBH (DE) | 2017-09-26 | — | — | US | disclosed |
| WO-2017157735-A1 | SUBSTITUTED SULFONYL AMIDES FOR CONTROLLING ANIMAL PESTS | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2017-09-21 | — | — | WO | disclosed |
| US-9458155-B2 | Pyrido[4,3-b]indoles containing rigid moieties | MEDIVATION TECHNOLOGIES, INC (US) | 2016-10-04 | — | — | US | disclosed |
| US-20090252990-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | GRACEL DISPLAY INC. (KR) | 2009-10-08 | — | — | US | disclosed |
| US-20090184631-A1 | Novel red electroluminescent compounds and organic electroluminescent device using the same | GRACEL DISPLAY INC. (KR) | 2009-07-23 | — | — | US | disclosed |
| US-20090184629-A1 | Novel red electroluminescent compounds and organic electroluminescent device using the same | GRACEL DISPLAY INC. (KR) | 2009-07-23 | — | — | US | disclosed |
| US-20090179555-A1 | Novel red electroluminescent compounds and organic electroluminescent device using the same | GRACEL DISPLAY INC. (KR) | 2009-07-16 | — | — | US | disclosed |
| US-20090174316-A1 | Novel red electroluminescent compounds and organi electroluminescent device using the same | GRACEL DISPLAY INC. (KR) | 2009-07-09 | — | — | US | disclosed |
| US-20090174316-A1 | Novel red electroluminescent compounds and organi electroluminescent device using the same | GRACEL DISPLAY INC. (KR) | 2009-07-09 | — | — | US | disclosed |
| US-20090153037-A1 | Novel red electroluminescent compounds and organic electroluminescent device using the same | GRACEL DISPLAY INC. (KR) | 2009-06-18 | — | — | US | disclosed |
| EP-1077970-A1 | 11-ARYL-BENZO(B)NAPHTHO(2,3-D)FURANS AND 11-ARYL-BENZO(B)NAPHTHO(2,3-D)THIOPHENES USEFUL IN THE TREATMENT OF INSULIN RESISTANCE AND HYPERGLYCEMIA | AMERICAN HOME PRODUCTS CORPORATION (US) | 2001-02-28 | — | — | EP | disclosed |
| WO-1999058521-A1 | 11-ARYL-BENZO[B]NAPHTHO[2,3-D]FURANS AND 11-ARYL-BENZO[B]NAPHTHO[2,3-D]THIOPHENES USEFUL IN THE TREATMENT OF INSULIN RESISTANCE AND HYPERGLYCEMIA | AMERICAN HOME PRODUCTS CORPORATION (US) | 1999-11-18 | — | — | WO | disclosed |
| US-4375566-A | Process for producing ortho-alkylated phenols from anisoles | MITSUI TOATSU CHEMICALS, INC. (JP) | 1983-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355703-A1 | COMPOUNDS FOR THE INHIBITION OF INDOLEAMINE-2,3-DIOXYGENASE | IDO1, IDO2, INMT | KDM4E 362/4885LPAR1 366/4885CA1 2987/4885 |
| US-20240018139-A1 | NEW SMALL-MOLECULE COMPOUNDS FOR CONTROLLING ENDOSOMAL TOLL-LIKE RECEPTORS AND THERAPEUTIC AGENT FOR AUTOIMMUNE DISEASES USING SAME | TLR9, TLR8, TLR3 | KDM4E 3429/4885LPAR1 190/4885CA1 4784/4885 |
| US-20090252990-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | AOX1, LEF1, ODC1 | KDM4E 2236/4885LPAR1 1039/4885CA1 2343/4885 |
| US-20240228469-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | PCSK9, PCSK7, PCSK6 | KDM4E 3520/4885LPAR1 93/4885CA1 3414/4885 |
| US-20240217951-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | PCSK9, PCSK7, PCSK6 | KDM4E 3138/4885LPAR1 60/4885CA1 2778/4885 |
| US-20090184631-A1 | Novel red electroluminescent compounds and organic electroluminescent device using the same | ALDH1A2, ODC1, NDUFS2 | KDM4E 1602/4885LPAR1 2567/4885CA1 2388/4885 |
| US-20090174316-A1 | Novel red electroluminescent compounds and organi electroluminescent device using the same | ALPI, IK, ALDH1A2 | KDM4E 2833/4885LPAR1 1849/4885CA1 1588/4885 |
| US-20090153037-A1 | Novel red electroluminescent compounds and organic electroluminescent device using the same | NDUFS2, ALDH1A2, ODC1 | KDM4E 1792/4885LPAR1 2480/4885CA1 2517/4885 |
| US-20090184629-A1 | Novel red electroluminescent compounds and organic electroluminescent device using the same | IK, TYR, EYA2 | KDM4E 1716/4885LPAR1 2813/4885CA1 3199/4885 |
| US-20200288710-A1 | SUBSTITUTED SULPHONAMIDES FOR CONTROLLING ANIMAL PESTS | DDT, MPST, STOM | KDM4E 430/4885LPAR1 4048/4885CA1 1251/4885 |
| US-20090179555-A1 | Novel red electroluminescent compounds and organic electroluminescent device using the same | NDUFS2, ALDH1A2, ODC1 | KDM4E 1792/4885LPAR1 2480/4885CA1 2517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.